FDA wrong to clear ReGen Biologics knee implant

Published October 19, 2010

FDA wrong to clear ReGen Biologics knee implant
The Food & Drug Administration decided it was wrong to clear a knee implant made by ReGen Biologics Inc. (OTC:RGBO) in 2008, over-riding the objections of FDA reviewers. The rescission means Hackensack, New Jersey-based ReGen has to keep its Menaflex device off the market until it can prove its safety and effectiveness to the FDA’s satisfaction.
Read more on MedCity News

T.I. to return to prison for 11 more months
T.I. to return to prison for 11 more months
Read more on Atlanta Journal-Constitution